“…The suitable nuclear characteristics of 89 Zr (supplementary Table-1) makes it a promising radionuclide in nuclear medicine for immuno-PET, bio-distribution studies, tracking and quantification of monoclonal antibodies (mAbs) 5 .Ever since its first utilization by Link et al in 1986, 89 Zrbased PET imaging has been investigated for a wide variety of cancer-related targets, including human epidermal growth factor receptor 2, prostate-specific membrane antigen, splice variant v6 of CD44, vascular endothelial growth factor, etc 6 . Another radioisotope of Zr; 88 Zr (T½ =83.4 d) is used as tracers for Zr radiochemistry studies and also for studying the radiochemistry and electrophoretic behavior of Zr(IV) at nanogram amounts 7 . 88,89 Zr may also be suitable therapeutic radionuclide in cellular level, since both of these radionuclides have high intensity auger electrons (supplementary Table1).…”